WallStreetZenWallStreetZen

NASDAQ: AGIO
Agios Pharmaceuticals Inc Stock

$24.22-0.53 (-2.14%)
Updated Oct 2, 2023
AGIO Price
$24.22
Fair Value Price
$26.10
Market Cap
$1.35B
52 Week Low
$21.07
52 Week High
$31.87
P/E
-6.37x
P/B
1.4x
P/S
78.16x
PEG
N/A
Dividend Yield
N/A
Revenue
$20.15M
Earnings
-$210.05M
Gross Margin
87.1%
Operating Margin
-1,042.56%
Profit Margin
-1,042.6%
Debt to Equity
0.13
Operating Cash Flow
-$299M
Beta
1.12
Next Earnings
Oct 18, 2023
Ex-Dividend
N/A
Next Dividend
N/A

AGIO Overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AGIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AGIO ($24.22) is undervalued by 7.22% relative to our estimate of its Fair Value price of $26.10 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AGIO ($24.22) is not significantly undervalued (7.22%) relative to our estimate of its Fair Value price of $26.10 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AGIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AGIO due diligence checks available for Premium users.

Be the first to know about important AGIO news, forecast changes, insider trades & much more!

AGIO News

Valuation

AGIO fair value

Fair Value of AGIO stock based on Discounted Cash Flow (DCF)
Price
$24.22
Fair Value
$26.10
Undervalued by
7.22%
AGIO ($24.22) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AGIO ($24.22) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AGIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AGIO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-6.37x
Industry
14.19x
Market
12.38x

AGIO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.4x
Industry
5.05x
AGIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

AGIO's financial health

Profit margin

Revenue
$6.7M
Net Income
-$83.8M
Profit Margin
-1,248.6%
AGIO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AGIO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.1B
Liabilities
$120.9M
Debt to equity
0.13
AGIO's short-term assets ($757.24M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AGIO's short-term assets ($757.24M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AGIO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AGIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$66.7M
Investing
$47.1M
Financing
$237.0k
AGIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AGIO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
AGIO$1.35B-2.14%-6.37x1.40x
ZNTL$1.40B-1.00%-4.14x2.68x
CLDX$1.29B-0.55%-11.36x4.66x
ABCL$1.29B-3.04%-17.15x1.08x
RCUS$1.29B-3.68%-4.37x2.28x

Agios Pharmaceuticals Stock FAQ

What is Agios Pharmaceuticals's quote symbol?

(NASDAQ: AGIO) Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol AGIO. Agios Pharmaceuticals stock quotes can also be displayed as NASDAQ: AGIO.

If you're new to stock investing, here's how to buy Agios Pharmaceuticals stock.

What is the 52 week high and low for Agios Pharmaceuticals (NASDAQ: AGIO)?

(NASDAQ: AGIO) Agios Pharmaceuticals's 52-week high was $31.87, and its 52-week low was $21.07. It is currently -24% from its 52-week high and 14.95% from its 52-week low.

How much is Agios Pharmaceuticals stock worth today?

(NASDAQ: AGIO) Agios Pharmaceuticals currently has 55,739,306 outstanding shares. With Agios Pharmaceuticals stock trading at $24.22 per share, the total value of Agios Pharmaceuticals stock (market capitalization) is $1.35B.

Agios Pharmaceuticals stock was originally listed at a price of $31.28 in Jul 24, 2013. If you had invested in Agios Pharmaceuticals stock at $31.28, your return over the last 10 years would have been -22.57%, for an annualized return of -2.53% (not including any dividends or dividend reinvestments).

How much is Agios Pharmaceuticals's stock price per share?

(NASDAQ: AGIO) Agios Pharmaceuticals stock price per share is $24.22 today (as of Oct 2, 2023).

What is Agios Pharmaceuticals's Market Cap?

(NASDAQ: AGIO) Agios Pharmaceuticals's market cap is $1.35B, as of Oct 3, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Agios Pharmaceuticals's market cap is calculated by multiplying AGIO's current stock price of $24.22 by AGIO's total outstanding shares of 55,739,306.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.